Lightnews — Scholar-powered news

Precision Oncology News @preconcnews.bsky.social · 10h

The company expects top-line results in 2026 from this group of the basket trial testing the drug plixorafenib as a next-generation monotherapy.

First Interim Analysis of Fore's BRAF Inhibitor Demonstrates Preliminary Efficacy in CNS Tumors

www.precisionmedicineonline.com

1

Precision Oncology News @preconcnews.bsky.social · 17h

The initiative comprises academic institutions, charities, and companies pursuing a broad range of novel diagnostic and therapeutic approaches.

Irish Precision Oncology Consortium Enters Second Phase With €28M

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 1d

The company expects top-line results in 2026 from this group of the basket trial testing the drug plixorafenib as a next-generation monotherapy.

First Interim Analysis of Fore's BRAF Inhibitor Demonstrates Preliminary Efficacy in CNS Tumors

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 6d

Some genetics experts felt the event raised awareness of the importance of testing, while others had mixed feelings amid growing healthcare access worries.

Cancer Screening Event Puts Spotlight on Improving Test, Counseling, Downstream Services Access

www.precisionmedicineonline.com

1

Precision Oncology News @preconcnews.bsky.social · 6d

The study found that patients with luminal B subtype prostate cancer benefited from the addition of hormone therapy to post-surgery radiation.

Phase II Trial Validates Predictive Biomarker for Hormone Therapy Use in Prostate Cancer

www.precisionmedicineonline.com

1 3

Precision Oncology News @preconcnews.bsky.social · 7d

The drugmaker is transitioning to Trialbee's Honey platform to better screen patients, including for biomarker information, before sending them to trial sites.

BMS, Trialbee Partner to Improve Clinical Trial Matching

www.precisionmedicineonline.com

1

Precision Oncology News @preconcnews.bsky.social · 8d

The study found that patients with luminal B subtype prostate cancer benefited from the addition of hormone therapy to post-surgery radiation.

Phase II Trial Validates Predictive Biomarker for Hormone Therapy Use in Prostate Cancer

www.precisionmedicineonline.com

1

Precision Oncology News @preconcnews.bsky.social · 8d

The drugmaker is transitioning to Trialbee's Honey platform to better screen patients, including for biomarker information, before sending them to trial sites.

BMS, Trialbee Partner to Improve Clinical Trial Matching

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 8d

The BrightKaire test converts stem cells to neurons and exposes those neurons to different antidepressants to determine how patients might react to treatments.

With Rebrand and US Launch of Depression Test, NeuroKaire Enters Precision Psychiatry Testing Market

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 8d

Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, according to Tufts researchers.

Commercial Insurers Often Impose Extra Restrictions on Gene, Cell Therapy Coverage, Analysis Finds

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 12d

Retrospective research from more than a decade ago demonstrated the potential benefit, but it hadn't been confirmed in a trial before now.

Aspirin Decreases Disease Recurrence by 50 Percent for PI3K-Altered Colorectal Cancer, Study Finds

www.precisionmedicineonline.com

1 2

Precision Oncology News @preconcnews.bsky.social · 12d

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo CAR T-cell candidate.

Aera Shooting for In Vivo CAR T Trials in Autoimmune Disease by Mid-2026

www.precisionmedicineonline.com

1

Precision Oncology News @preconcnews.bsky.social · 13d

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo CAR T-cell candidate.

Aera Shooting for In Vivo CAR-T Trials in Autoimmune Disease by Mid-2026

www.precisionmedicineonline.com

1

Precision Oncology News @preconcnews.bsky.social · 16d

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated evidence can support new product approvals.

FDA Mulling Existing Data Types Sponsors May Leverage to Speed Cell, Gene Therapies to Market

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 19d

A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on FOLFIRINOX than on gemcitabine plus nab-paclitaxel.

Tempus Pancreatic Cancer Classifier Shows Promise in Guiding First-Line Chemo Choice in Study

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 20d

A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on FOLFIRINOX than on gemcitabine plus nab-paclitaxel.

Tempus Pancreatic Cancer Classifier Shows Promise in Guiding First-Line Chemo Choice in Study

www.precisionmedicineonline.com

2 1

Precision Oncology News @preconcnews.bsky.social · 21d

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing arthritis drug delivery.

Researchers Developing 'Chronogenetic' Implant to Time Arthritis Treatment to Circadian Rhythms

www.precisionmedicineonline.com

1

Precision Oncology News @preconcnews.bsky.social · 22d

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing arthritis drug delivery.

Researchers Developing 'Chronogenetic' Implant to Time Arthritis Treatment to Circadian Rhythms

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 26d

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has shown promise in preclinical studies.

Mass General Researchers Move Toward Human Testing of CRISPR Therapy for Rare Vascular Disease

www.precisionmedicineonline.com

1

Precision Oncology News @preconcnews.bsky.social · 27d

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has shown promise in preclinical studies.

Mass General Researchers Move Toward Human Testing of CRISPR Therapy for Rare Vascular Disease

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 27d

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million non-dilutive term loan.

Octave Bioscience Pushing Multiple Sclerosis Blood Test Toward Broader Clinical Adoption

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 28d

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million non-dilutive term loan.

Octave Bioscience Pushing Multiple Sclerosis Blood Test Toward Broader Clinical Adoption

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · 29d

The agency said it will accept data from single-arm trials in its newly released Rare Disease Evidence Principles, but experts pointed out this is largely already happening.

FDA Unveils Regulatory Review Principles for Extremely Rare Disease Treatments

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · Sep 8

The agency said it will accept data from single-arm trials in its newly released Rare Disease Evidence Principles, but experts pointed out this is largely already happening.

FDA Unveils Regulatory Review Principles for Extremely Rare Disease Treatments

www.precisionmedicineonline.com

Precision Oncology News @preconcnews.bsky.social · Sep 7

An analysis found APOE ε4 carriers have a slightly higher risk of brain bleeds if they're taking the anticoagulant, but it likely won't lead to a safety label update, experts said.

Study Raises Questions About How to Manage Brain Bleed Risk Among Known APOE4 Carriers on Eliquis

www.precisionmedicineonline.com

1